Lubiprostone for the treatment of opioid-induced bowel dysfunction

Bibliography

• Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010;13:401-35
   PubMed Web of Science ®Google Scholar
• Boudreau D, Von Korff M, Rutter CM, Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009;18:1166-75
   PubMed Web of Science ®Google Scholar
• Ruoff GE. Assessing pain as the fifth vital sign. Postgrad Med 2002;112(Suppl 1):4-7
   PubMedGoogle Scholar
• Cook SF, Lanza L, Zhou X, Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther 2008;27:1224-32
   PubMed Web of Science ®Google Scholar
• Glare P, Lickiss JN. Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J Pain Symptom Manage 1992;7:369-71
   PubMed Web of Science ®Google Scholar
• Portenoy RK. Constipation in the cancer patient: causes and management. Med Clin North Am 1987;71:303-11
   PubMed Web of Science ®Google Scholar
• Schmier JK, Palmer CS, Flood EM, Gourlay G. Utility assessments of opioid treatment for chronic pain. Pain Med 2002;3:218-30
   PubMed Web of Science ®Google Scholar
• Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage 2008;35:103-13
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A Suppl):11S-18S
   PubMed Web of Science ®Google Scholar
• Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 1998;12:375-82
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80
   PubMed Web of Science ®Google Scholar
• Gomes I, Gupta A, Filipovska J, A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 2004;101:5135-9
   PubMed Web of Science ®Google Scholar
• Manara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther 1986;237:945-9
   PubMed Web of Science ®Google Scholar
• Porreca F, Cowan A, Raffa RB, Tallarida RJ. Ketazocines and morphine: effects on gastrointestinal transit after central and peripheral administration. Life Sci 1983;32:1785-90
   PubMed Web of Science ®Google Scholar
• Thorn SE, Wattwil M, Lindberg G, Sawe J. Systemic and central effects of morphine on gastroduodenal motility. Acta Anaesthesiol Scand 1996;40:177-86
   PubMed Web of Science ®Google Scholar
• Green AF. Comparative effects of analgesics on pain threshold, respiratory frequency and gastrointestinal propulsion. Br J Pharmacol Chemother 1959;14:26-34
   PubMed Web of Science ®Google Scholar
• Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs 2007;16:181-94
   PubMed Web of Science ®Google Scholar
• Beloosesky Y, Grinblat J, Weiss A, Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med 2003;163:803-8
   PubMed Web of Science ®Google Scholar
• Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum 2001;44:1201-9
   PubMed Web of Science ®Google Scholar
• Lacy BE, Chey WD. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother 2009;10:143-52
   PubMed Web of Science ®Google Scholar
• Moss J, Rosow CE. Development of peripheral opioid antagonists' new insights into opioid effects. Mayo Clin Proc 2008;83:1116-30
   PubMed Web of Science ®Google Scholar
• Allan L, Hays H, Jensen NH, Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1154-8
   PubMed Web of Science ®Google Scholar
• Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005;7:R1046-51
   PubMed Web of Science ®Google Scholar
• Schug SA, Zech D, Grond S, A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage 1992;7:259-66
   PubMed Web of Science ®Google Scholar
• Kaufman PN, Krevsky B, Malmud LS, Role of opiate receptors in the regulation of colonic transit. Gastroenterology 1988;94:1351-6
   PubMed Web of Science ®Google Scholar
• McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev 2008:CD006332
   Google Scholar
• Gonenne J, Camilleri M, Ferber I, Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005;3:784-91
   PubMed Web of Science ®Google Scholar
• Paulson DM, Kennedy DT, Donovick RA, Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction – a 21-day treatment-randomized clinical trial. J Pain 2005;6:184-92
   PubMed Web of Science ®Google Scholar
• Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 22 February2011. [Epub ahead of print]
   Google Scholar
• Lowenstein O, Leyendecker P, Lux EA, Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010;10:12
   PubMedGoogle Scholar
• Bao HF, Liu L, Self J, A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am J Physiol 2008;295:G234-51
   PubMed Web of Science ®Google Scholar
• Amitiza® (lubiprostone) package insert. Sucampo Pharmaceuticals, Besthesda, MD; 2006
   Google Scholar
• Cuppoletti J, Malinowska DH, Tewari KP, SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004;287:C1173-83
   PubMed Web of Science ®Google Scholar
• Fei G, Wang YZ, Liu S, Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon. Am J Physiol 2009;296:G823-32
   Google Scholar
• Ueno R, Osama H, Habe T, SPI-0211 increases intestinal fluid secretion and chloride concentrations without altering serum electrolyte levels. Gastroenterology 2004;126:A298
   Web of Science ®Google Scholar
• Bassil AK, Borman RA, Jarvie EM, Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 2008;154:126-35
   PubMed Web of Science ®Google Scholar
• Camilleri M, Bharucha AE, Ueno R, Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol 2006;290:G942-7
   PubMed Web of Science ®Google Scholar
• Grider JR, Jin JG. Distinct populations of sensory neurons mediate the peristaltic reflex elicited by muscle stretch and mucosal stimulation. J Neurosci 1994;14:2854-60
   PubMed Web of Science ®Google Scholar
• Fei G, Raehal K, Liu S, Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. J Pharmacol Exp Ther 2010;334:333-40
   PubMed Web of Science ®Google Scholar
• Cryer BL, Katz S, Vallejo R, A phase 3, randomized, double-blind, placebo-controlled clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction in patients with chronic, non-cancer pain. Gastroenterology 2010;138:906
   Google Scholar
• Sucampo Pharmaceuticals, Inc. website. Available from: http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-newsArticle&ID=1424833&highlight= [Last accessed 15 December 2010]
   Google Scholar
• Rivera E, Wahle A, Joswick TR, Ueno R. Lubiprostone, a novel type-2 chloride channel (ClC-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation. Gastroenterology 2007;132:A191-2
   Web of Science ®Google Scholar
• Sprenger C, Copa A, Morganroth J, Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation, on clinical electrocardiogram results. Gastroenterology 2007;132:A325
   Web of Science ®Google Scholar
• Slatkin N, Thomas J, Lipman AG, Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009;7:39-46
   PubMedGoogle Scholar
• Thomas J, Karver S, Cooney GA, Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-43
   PubMed Web of Science ®Google Scholar
• Wong BS, Rao AS, Camilleri M, The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. Alimentary Pharmacol Ther 2010;32:884-93
   PubMed Web of Science ®Google Scholar
• Johanson JF, Drossman DA, Panas R, Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Alimentary Pharmacol Ther 2008;27:685-96
   PubMed Web of Science ®Google Scholar
• Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-7
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chey WD, Johanson JF, Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Alimentary Pharmacol Ther 2009;29:329-41
   PubMed Web of Science ®Google Scholar
• Sweetser S, Busciglio IA, Camilleri M, Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol 2009;296:G295-301
   PubMed Web of Science ®Google Scholar
• Moeser AJ, Nighot PK, Engelke KJ, Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol 2007;292:G647-56
   PubMed Web of Science ®Google Scholar
• Cuppoletti J, Malinowska DH, Tewari K, Methadone, but not morphine, inhibits stimulated chloride currents in ClC-2 transfected cells in culture. Gastroenterology 2010;138:1010
   Web of Science ®Google Scholar